Asklepios BioPharmaceutical, Inc.
https://www.askbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Asklepios BioPharmaceutical, Inc.
Bayer Spend On Start-Ups Growing By Leaps And Bounds
The German group is putting another €1.3bn into its Leaps by Bayer investment arm until the end of 2024 to support new companies that are "shifting core paradigms in the sectors of health and agriculture."
Bayer Pharma R&D Head Tackles Challenge Of Prioritizing Promising Assets
Nearly a year into the job, research chief Christian Rommel tells Scrip he is impressed with Bayer's arm's length approach to running acquired firms like AskBio and BlueRock and the task ahead is to deliver on the potential they offer, while getting later-stage projects across the approvals finishing line.
The Top Five (Non-COVID) Pharma Stories Of 2021
The emergence and rapid spread of the Omicron variant has kept COVID-19 firmly in the headlines but the biopharma industry has had plenty on its plate on top of tackling the pandemic. Scrip has taken a look back at five of the biggest non-COVID-19 story themes of 2021 in no particular order.
Bayer Consolidates Next-Generation Gene Editing Focus With Mammoth Deal
The German major will collaborate with the US biotech to develop CRISPR gene-editing therapies, solidifying its interest in next-generation therapeutics.
Company Information
- Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- Actus Therapeutics, Inc.
- AskBio
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics
- BrainVectis